2024
Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient
Marvin J, Trubin P, Azar M. Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient. Transplant Infectious Disease 2024, 26: e14329. PMID: 38971997, DOI: 10.1111/tid.14329.Peer-Reviewed Original ResearchA Patient With Type 1 Diabetes and Acute Rhinosinusitis
Roman F, Azar M, Trubin P. A Patient With Type 1 Diabetes and Acute Rhinosinusitis. JAMA 2024, 331: 1586-1587. PMID: 38630502, DOI: 10.1001/jama.2024.0642.Peer-Reviewed Original ResearchAtypical pneumonia testing in transplant recipients
Feller F, Trubin P, Malinis M, Vogel J, Merwede J, Peaper D, Azar M. Atypical pneumonia testing in transplant recipients. Transplant Infectious Disease 2024, 26: e14256. PMID: 38430482, DOI: 10.1111/tid.14256.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationTransplant recipientsPathogens of pneumoniaAtypical pneumoniaAugmented immunosuppressionAtypical pathogensTest positivity rateChimeric antigen receptor T cellsHematopoietic stem cell transplant recipientsDiagnosis of atypical pneumoniaPositive rateCases of mycoplasma infectionStem cell transplantationSolid organ transplantationRetrospective cohort studyMycoplasma infectionImmunocompromised patientsCell transplantationAnalysis of diagnostic testsDiagnostic yieldTransplant cohortPost-transplantationT cellsCohort studyRates of testingLarone’s Medically Important Fungi: A Guide to Identification, 7 Edition - Volume 30, Number 3—March 2024 - Emerging Infectious Diseases journal - CDC
Azar M. Larone’s Medically Important Fungi: A Guide to Identification, 7 Edition - Volume 30, Number 3—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 625-626. PMCID: PMC10902529, DOI: 10.3201/eid3003.231623.Peer-Reviewed Original ResearchLung infections due to emerging fungal pathogens
Roman F, Pischel L, Azar M. Lung infections due to emerging fungal pathogens. Current Opinion In Pulmonary Medicine 2024, 30: 258-265. PMID: 38411158, DOI: 10.1097/mcp.0000000000001059.Peer-Reviewed Original ResearchConceptsEndemic mycosesManagement of pulmonary infectionsFungal pathogensPathogenic fungiAntifungal prophylaxisBlastomyces speciesFungal infectionsFungal organismsAspergillus moldsEnvironmental changesImmunocompromised hostsPulmonary infectionTherapeutic challengeLung infectionMycosesClinical evidenceClinical managementIncreased incidencePulmonary diseaseEnlarged poolDisease burdenInfectionLomentosporaScedosporiumDiagnostic capabilitiesClinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience
Feller F, Azar M, Marvin J, Cohen E, Virmani S, Malinis M. Clinical outcomes of SARS‐CoV‐2 infection in kidney transplant recipients on belatacept: a single‐center experience. Transplant Infectious Disease 2024, 26: e14253. PMID: 38351494, DOI: 10.1111/tid.14253.Peer-Reviewed Original ResearchThe respiratory syncytial virus vaccines are here: Implications for solid organ transplantation
Trubin P, Azar M, Kotton C. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation. American Journal Of Transplantation 2024, 24: 897-904. PMID: 38341028, DOI: 10.1016/j.ajt.2024.02.003.Peer-Reviewed Original ResearchRespiratory syncytial virusSolid organ transplantationLower respiratory tract diseaseHigh risk of infectious complicationsBurden of RSV diseaseOrgan transplantationRisk of infectious complicationsRespiratory syncytial virus vaccineRespiratory tract diseaseCenters for Disease Control and Prevention's Advisory CommitteeOrgan transplant recipientsSolid organ recipientsPoor clinical outcomesFood and Drug AdministrationRSV F glycoproteinRespiratory virus vaccinesRSV diseaseInfectious complicationsTransplant recipientsClinical outcomesSyncytial virusClinical decision-makingImmunocompromised individualsOrgan recipientsImmunization PracticesClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2023
A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care
Trubin P, Azar M. A fast-track to fungal diagnosis: the potential of molecular diagnostics for fungi at the point of care. Expert Review Of Molecular Diagnostics 2023, 24: 143-146. PMID: 37991006, DOI: 10.1080/14737159.2023.2287504.Peer-Reviewed Original ResearchA Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective
Azar M. A Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective. CHEST Journal 2023, 165: 559-572. PMID: 37813181, DOI: 10.1016/j.chest.2023.10.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFungal pneumoniaAppropriate diagnostic testingClinical syndromeDiagnostic testingLower respiratory tract infectionsNon-resolving pneumoniaRespiratory tract infectionsInfectious diseases perspectiveTract infectionsRadiographic patternsCommon causeEpidemiologic exposuresCorrect diagnosisRisk populationsPneumoniaDiagnostic approachHost factorsDisease perspectiveConstellation of factorsPatientsSyndromeInfectionEpidemiologyIncidenceDiagnosisResponse to comment on “Dosing implications for liposomal amphotericin B in pregnancy”
O'Grady N, Davis M, McManus D, Topal J, Azar M, Briggs N. Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 992-992. PMID: 37701938, DOI: 10.1002/phar.2864.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsActive and Passive Immunization Approaches in Transplant Recipients
Ringer M, Azar M, Malinis M. Active and Passive Immunization Approaches in Transplant Recipients. Current Transplantation Reports 2023, 10: 188-198. DOI: 10.1007/s40472-023-00406-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSolid organ transplant recipientsImmune responseTransplant recipientsActive immunizationReviewThe COVID-19 pandemicMonoclonal antibodiesSARS-CoV2 vaccinesOrgan transplant recipientsDose of vaccinePassive immunization approachesTiming of vaccinationPassive immunization strategiesUse of adjuvantsBooster dosesConvalescent plasmaClinical efficacyPassive immunizationPoor outcomePassive immunityImmunization approachVaccinationImmunization strategiesImmunizationFurther studiesCOVID-19 pandemicRapid antimicrobial resistance detection methods for bloodstream infection in solid organ transplantation: Proposed clinical guidance, unmet needs, and future directions
Turbett S, Banach D, Bard J, Gandhi R, Letourneau A, Azar M. Rapid antimicrobial resistance detection methods for bloodstream infection in solid organ transplantation: Proposed clinical guidance, unmet needs, and future directions. Transplant Infectious Disease 2023, 25: e14113. PMID: 37594214, DOI: 10.1111/tid.14113.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUnmet needSolid organ transplant recipientsOrgan transplant recipientsSolid organ transplantationTransplant infectious diseasesEffective antimicrobial therapyPositive blood culturesFast institutionSOT recipientsTransplant recipientsDiagnostic stewardshipBloodstream infectionsAntimicrobial therapyBlood culturesClinical guidanceOrgan transplantationConsensus conferenceClinical practiceInfectious diseasesClinical microbiologyAmerican SocietyTransplantationResistance detectionBacterial resistanceRecipientsInclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors
Luther V, Barsoumian A, Konold V, Vijayan T, Balba G, Benson C, Blackburn B, Cariello P, Perloff S, Razonable R, Acharya K, Azar M, Bhanot N, Blyth D, Butt S, Casanas B, Chow B, Cleveland K, Cutrell J, Doshi S, Finkel D, Graber C, Hazra A, Hochberg N, James S, Kaltsas A, Kodiyanplakkal R, Lee M, Marcos L, Lora A, Moore C, Nnedu O, Osorio G, Paras M, Reece R, Salas N, Sanasi-Bhola K, Schultz S, Serpa J, Shnekendorf R, Weisenberg S, Wooten D, Zuckerman R, Melia M, Chirch L. Inclusion, Diversity, Access, and Equity in Infectious Diseases Fellowship Training: Tools for Program Directors. Open Forum Infectious Diseases 2023, 10: ofad289. PMID: 37397270, PMCID: PMC10313091, DOI: 10.1093/ofid/ofad289.Peer-Reviewed Original ResearchCurrent Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation
Trubin P, Azar M. Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation. Infectious Disease Clinics Of North America 2023, 37: 617-640. PMID: 37142510, DOI: 10.1016/j.idc.2023.03.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSolid organ transplant recipientsOrgan transplant recipientsFirst-choice agentsSolid organ transplantationAppropriate clinical contextTransplant recipientsInterstitial pneumoniaTrimethoprim-sulfamethoxazoleOptimal treatmentPneumocystis pneumoniaOrgan transplantationInfection manifestsPrevention strategiesNucleic acid amplificationDiagnostic testingRadiographic imagingTissue samplingClinical contextLung fluidCurrent conceptsHost susceptibilityPneumoniaAcid amplificationTreatmentProphylaxisDosing implications for liposomal amphotericin B in pregnancy
O'Grady N, McManus D, Briggs N, Azar M, Topal J, Davis M. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 452-462. PMID: 36862037, DOI: 10.1002/phar.2784.Peer-Reviewed Original ResearchConceptsIdeal body weightLiposomal amphotericin BMucocutaneous leishmaniasisBody weightAmphotericin BInfectious Diseases SocietyTotal body weightPregnant patientsDiseases SocietyAmerica guidelinesPreferred agentPregnancyParasitic infectionsOpportunistic fungalAdverse effectsPatientsTreatmentLeishmaniasisLambsDaysUse of lambsGuidelinesRegimensWeightFetusesTransplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases
Puius Y, Azar M, Tsai H, Vergidis P, Harris C, Anjan S, Barros N, Belga S, Chuang S, Czeresnia J, Goel S, Ince D, Luk A, Majeed A, Multani A, Obeid K, Swaminathan N. Transplantid.net: A Pilot Crowdsourced, Living, Online Library of Resources for the Teaching and Practice of Transplant Infectious Diseases. Open Forum Infectious Diseases 2023, 10: ofad081. PMID: 36861087, PMCID: PMC9969731, DOI: 10.1093/ofid/ofad081.Peer-Reviewed Original Research
2022
The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates
Palacios C, Medvedeva N, Cheung H, Cohen E, Azar M, Malinis M. The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates. Transplant Infectious Disease 2022, 25: e13999. PMID: 36484433, DOI: 10.1111/tid.13999.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionLT candidatesIndeterminate IGRALTBI testingTuberculosis infectionCascade of carePost-liver transplantLiver transplant candidatesProportion of patientsRetrospective chart reviewTB-endemic countriesInterferon-gamma releaseTreatment completion ratesCompletion ratesLTBI treatmentPositive IGRATB reactivationCare cascadeTreatment-naïveChart reviewSecondary outcomesTransplant candidatesPrimary outcomeTreatment initiationChest imaging535. Evaluation of the BioFire Blood Culture Identification (BCID2) panel for transplant recipients with a bloodstream infection
Palacios C, Peaper D, Malinis M, Malinis M, Perreault S, Cohen E, Vogel J, Azar M. 535. Evaluation of the BioFire Blood Culture Identification (BCID2) panel for transplant recipients with a bloodstream infection. Open Forum Infectious Diseases 2022, 9: ofac492.588. PMCID: PMC9752191, DOI: 10.1093/ofid/ofac492.588.Peer-Reviewed Original ResearchBone marrow transplant recipientsTransplant recipientsBloodstream infectionsBlood culturesPositive blood culturesClinical trialsPrimary investigatorSolid organ recipientsMarrow transplant recipientsRetrospective chart reviewYear of transplantationAntimicrobial susceptibility resultsBlood Culture Identification PanelBSI eventsChart reviewOptimal therapyOrgan recipientsMean ageMultiplex PCR panelSame patientGeneral populationPolymicrobial culturesCandida sppPeripheral sitesRecipientsAntiviral Treatment of Coronavirus Disease-2019 Pneumonia
Radcliffe C, Malinis M, Azar M. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Clinics In Chest Medicine 2022, 44: 279-297. PMID: 37085220, PMCID: PMC9701636, DOI: 10.1016/j.ccm.2022.11.008.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus diseaseCoronavirus 2 infectionDirect acting antiviralsAdditional clinical trialsReal-world studyCOVID-19Acting antiviralsAntiviral treatmentTherapeutic optionsAvailable therapiesClinical trialsDisease progressionInpatient treatmentHigh riskEarly pandemicMonoclonal antibodiesDiseaseTreatmentMorbidityPandemicPneumoniaOutpatients